Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12919538 | 0.81 | POLB (0.47) | CYP11B1CYP11B2CYP3A4RECQL | |
| SCHEMBL302475 | 0.79 | SMN1; SMN2 (0.51) | CYP11B1CYP11B2MAOBSIGMAR1ADRA2C | |
| SCHEMBL973852 | 0.79 | IDO1 (0.41) | SIGMAR1 | |
| SCHEMBL152660 | 0.76 | CYP19A1 (0.48) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL16760957 | 0.72 | SIGMAR1 (0.56) | CYP11B1CYP11B2MAOAMAOBSIGMAR1 | |
| SCHEMBL13242846 | 0.69 | PRMT6 (0.62) | CYP11B1CYP11B2SIGMAR1 | |
| SCHEMBL30469295 | 0.69 | PRMT6 (0.68) | SIGMAR1 | |
| SCHEMBL833409 | 0.69 | PRMT6 (0.68) | SIGMAR1 | |
| SCHEMBL13242853 | 0.69 | CYP11B1 (0.47) | CYP11B1CYP11B2MAOAMAOBCYP19A1 | |
| SCHEMBL374345 | 0.69 | ALDH1A1 (0.59) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840592-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230008878-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | CITIZENS BANK, N.A., AS COLLATERAL AGENT, NATIONAL BANKING ASSOCIATION | 2023-01-12 | — | — | US | disclosed |
| EP-3888694-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | Molecular Insight Pharmaceuticals, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008878-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | NISCH, TPO, UGT1A9 | CYP11B1 2266/4885CYP11B2 2303/4885MAOA 155/4885 |
| US-11840592-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | NISCH, TPO, UGT1A9 | CYP11B1 2266/4885CYP11B2 2303/4885MAOA 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.